Data from the control arm of adjuvant bladder cancer trials (CM274 and Ambassador250) suggests ~35% get no further therapy after relapse (accounting for censoring). Excellent sites. Chemo is globally available. Regular CT follow should catch early & treat. Any easy explanations?

Tom Powles JAMA Oncology gives us key parts of the answer👇. 34% pts with advanced cancer prioritize symptom managem over life extension. In GeriOnc these No. are even much higher as 2 teams shown us Enrique Soto.
Patient-centered care=> ~1/3 refuse Tx Mark Lewis Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 William Dale, MD, PhD, FASCO